Island Pharmaceuticals

Island Pharmaceuticals company information, Employees & Contact Information

Island (ASX: ILA) is a drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases. We have a lead asset – ISLA-101 - that was initially developed by our wholly-owned subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquitoes (or vector) borne diseases. Dengue fever is the very definition of an unmet medical need. While 390 million humans are infected each year, it is thought that around 30-50% of people with the disease do not present with symptoms, enabling the virus to spread within communities. Warming global climates are accelerating the presence of mosquito-borne viruses that can cause death to the US, Europe and Australia There is no specific pharmaceutical treatment and the one vaccine which exists is available to a highly restricted audience. Island has repurposed ISLA-101, an antiviral oral drug to treat mosquito-borne viruses (eg dengue fever / Zika) and intends to complete Phase II studies with a significantly de-risked clinical program.

Company Details

Employees
3
Address
697 Burke Road Camberwell,, Suite 201,australia
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Race Oncology.
HQ
Melbourne, New South Wales
Looking for a particular Island Pharmaceuticals employee's phone or email?

Island Pharmaceuticals Questions

Top Island Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant